AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML.
about
The Aryl Hydrocarbon Receptor Relays Metabolic Signals to Promote Cellular RegenerationAn advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imagingDo AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesIn Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaTranslating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity.Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis.Cancer stem cell-directed therapies: recent data from the laboratory and clinic.Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias.Transforming human blood stem and progenitor cells: a new way forward in leukemia modeling.Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.Single-cell mass cytometry adapted to measurements of the cell cycle.Targeting stem cells-clinical implications for cancer therapy.A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology GroupConcise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cellsRight on target: eradicating leukemic stem cells.Human cancer growth and therapy in immunodeficient mouse models.Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.Establishment of a human multiple myeloma xenograft model in the chicken to study tumor growth, invasion and angiogenesis.In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid LeukemiaA clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemiaConcise review: Emerging concepts in clinical targeting of cancer stem cellsAcute myeloid leukemia stem cells and CD33-targeted immunotherapyAlkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell ActivityCan immunotherapy specifically target acute myeloid leukemic stem cells?Preferential eradication of acute myelogenous leukemia stem cells by fenretinide.Loss of imprinting of IGF2 and the epigenetic progenitor model of cancerSmall-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cellsDynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomesNormal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.Regulating the leukaemia stem cell.Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance.Acute myelogenous leukemia stem cells: from Bench to Bedside.Pharmacogenomic considerations of xenograft mouse models of acute leukemia.
P2860
Q26738807-69F5C33D-8FA2-49B6-9388-2C2E65C6F653Q27311229-D23E3404-6611-4443-A50B-4EE564518703Q27851686-8F8C810D-577B-452F-A091-8634D742A229Q28071384-EE625837-176B-430D-8E17-D4DCAE41BD6EQ28554677-A1C9BDCC-D8A1-40C2-B2F7-587515AA41E7Q30244186-01E25941-AFF6-40C2-A095-14D4DADFA259Q30975629-46D577E4-10A2-4FB5-BF0D-9C131E88EC1FQ33391372-9AACD3CC-92AD-40FB-BE78-40022FFBA93FQ33596048-878F0481-E04F-4D66-B53A-DCE02566A2E9Q33613165-6C795CCD-B29D-4DC9-81D8-0E8CD6EDED3FQ33722630-A11CC9B2-37F6-4324-BC14-44089DD17A5CQ33873844-55801B66-AD2D-476C-9195-5F84C5AAB066Q34207336-EEE9C32F-1D91-4FFC-94B6-98ABF621F196Q34281009-80C8E930-7F24-4D9B-BCF7-5F63015213ADQ34555251-E453AB40-6807-4BB9-8693-F4E2D7D85FB4Q34585047-268CC8B6-587C-4547-9357-7275EEE45191Q34647637-310FF5CA-441C-4B0B-945D-ECD298436E55Q35132225-EF3FB818-043C-470A-900F-BB0A75CE911BQ35545282-5DC4D96A-46E5-4B9D-A29C-ED91E56534EFQ35591409-54C9A164-77A6-4145-A507-7D0ABF9D6560Q35636675-F4AD8563-E6EE-46E4-8B43-44062678A62BQ35681332-D9363A68-6430-42C6-9E7D-97461579F721Q35885317-935AAB90-9CA2-4A2A-B04F-5986D5BE11A1Q35971159-E7C8C70E-1A3D-4A09-B184-2D34913C6CA7Q36058588-393E885E-BBA3-49B1-8F9E-65DACB651196Q36080036-9254E594-006A-453F-B480-BB3347DBAF44Q36694901-1912F05B-CAA5-4A10-B294-4016F41F9466Q36747742-FF94095B-4949-46FB-9C36-12B7D2379F99Q36813932-4A91768A-D018-4718-ADDC-ED118CC50F13Q36926120-CE5A66C9-7F5D-470B-8011-1B145CF5AC2FQ37163021-041FB65B-B0AE-4EED-AF22-A7E2406BA0DEQ37185272-17082B4C-29B4-4211-A534-39AE26A6180BQ37216232-A2CF06ED-4CFB-4392-8864-5602C3219727Q37297755-9D4F8566-F928-4719-9B03-C60F65E33A55Q37381414-F3404830-2472-4BCB-983F-600E31A79E1EQ37606183-BD687DA5-C26E-418C-BDFE-F2836B8942EAQ37644035-DE840ADD-BCF6-4BDB-B7A6-D92BB13FADABQ38010349-19528762-A8B9-4881-B7B5-B2BA831FDF34Q38020081-0CC12AC4-9E0D-4D71-9D95-148D29366284Q38061500-44592E37-5B97-44E9-9F9A-24624FC3249E
P2860
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
AML engraftment in the NOD/SCI ...... g of the heterogeneity of AML.
@en
type
label
AML engraftment in the NOD/SCI ...... g of the heterogeneity of AML.
@en
prefLabel
AML engraftment in the NOD/SCI ...... g of the heterogeneity of AML.
@en
P2093
P2860
P1433
P1476
AML engraftment in the NOD/SCI ...... g of the heterogeneity of AML.
@en
P2093
Ama Z Rohatiner
Bryan D Young
Christopher M Ridler
Claude Preudhomme
Daniel J Pearce
David Taussig
Dominique Bonnet
Lan-Lan Smith
T Andrew Lister
P2860
P304
P356
10.1182/BLOOD-2005-06-2325
P407
P50
P577
2005-10-18T00:00:00Z